Bliss Gvs Pharma Limited · NSE:BLISSGVS
Bliss Gvs Pharma — Q1 FY2020 Earnings Presentation
15 slides from Bliss Gvs Pharma's earnings presentation, Aug 21, 2019
Slide 1: Cover letter to stock exchanges
BLISS GVS PHARMA LTD. ~.s.s August 21, 2019 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India BSE Limited Plot no. C/1 G Block, Phiroze JeejeebhoyTowers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400001 Sym
Slide 2: Earnings Presentation Q1-FY20
ca.s~ss GVS Pharma limited Innovation I Integrity I Excellence EARNINGS PRESENTATION Q1-FY20
Slide 3: Executive Summary
Executive Summary OVERVIEW Incorporated in 1984, Bliss GVS Pharma Ltd., has more than 34 years of expertise in manufacturing, marketing & exporting of more than 250 Branded Formulations in various dosage forms with a major focus on the Sub-Sahara African region. It is a world leader in Supposito
Slide 4: Q1-FY20 Financial Highlights
Q1-FY20 Financial Highlights Q1-FY20 Performance (Standalone): • Operational Income : INR 1,152 Mn; Growth of 9.9% YoY • EBITDA : INR 368 Mn; Growth of 36.3% YoY • EBITDA Margin : 31.94%; Grown by 618 bps YoY • Net Profit : INR 239 Mn; Declined by 11.5% YoY • PAT Margin : 20.43%; Declined by 247 b
Slide 5: Q1-FY20 Operational Highlights
Q1-FY20 Operational Highlights Standalone - Operational Highlights Increase in the operational revenue for the quarter is on account of the export business mainly to Nigeria, France, Kenya, etc. Majority of the company’s sales are export driven and primarily to African countries. The increase in
Slide 6: Quarterly - Standalone Income Statement (Ind-AS)
Quarterly - Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) Q1-FY20 Q1-FY19 Y-o-Y Q4-FY19 Q-o-Q Operational Revenue 1,152 1,048 9.9% 1,061 8.6% Total Expenses 784 778 0.8% 922* (15.0)% EBITDA 368 270 36.3% 139 164.7% EBITDA Margins (%) 31.94% 25.76% 618 bps 13.10% NA Other Income 18 131 (8
Slide 7: Quarterly - Consolidated Income Statement (Ind-AS)
Quarterly - Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) Q1-FY20 Q1-FY19 Y-o-Y Q4-FY19 Q-o-Q Operational Revenue 2,115 2,053 3.0% 2,440 (13.3)% Total Expenses 1,625 1,647 (1.3)% 2,121 (23.4)% EBITDA 490 406 20.7% 319 53.6% EBITDA Margins (%) 23.17% 19.78% 339 bps 13.07% NA Other Incom
Slide 8: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) FY16 FY17* FY18* FY19* Q1-FY20 Operational Revenue 3,264 3,503 2,983 4,266 1,152 Total Expenses 2,299 2,493 2,098 3,335 784 EBITDA 965 1,010 885 931 368 EBITDA Margins (%) 29.56% 28.83% 29.67% 21.82% 31.94% Other Income 231 86 110 358 18 De
Slide 9: Standalone Balance Sheet (Ind-AS)
Standalone Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY18 FY19 PARTICULARS (INR Mn) FY18 FY19 EQUITIES & LIABILITIES ASSETS Non-current Assets 1,177 1,579 Shareholder Funds 5,414 6,033 (A) Property, Plant and Equipment 720 779 (A) Share Capital 103 103 (B) Capital Work-in-Progress 5 429 (B) Other
Slide 10: Historical Consolidated Income Statement (Ind-AS)
Historical Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) FY16 FY17* FY18* FY19* Q1-FY20 Operational Revenue 5,469 8,024 8,151 8,982 2,115 Total Expenses 3,912 5,996 6,180 7,406 1,625 EBITDA 1,557 2,028 1,971 1,576 490 EBITDA Margins (%) 28.47% 25.27% 24.18% 17.55% 23.17% Other Income 2
Slide 11: Consolidated Balance Sheet (Ind-AS)
Consolidated Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY18 FY19 PARTICULARS (INR Mn) FY18 FY19 EQUITIES & LIABILITIES ASSETS Shareholder Funds 5,362 6,460 Non-current Assets 1,702 2,113 (A) Share Capital 103 103 (A) Property, Plant and Equipment 1,263 1,348 (B) Other Equity 5,259 6,357 (B) Capita
Slide 12: Standalone Financial Highlights
Standalone Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 5,000 1400 800 1200 700 4,000 1000 600 19% 18% 3,000 800 30% 29% 30% 16% 16% 22% 500 2,000 600 400 400 1,000 300 200 3,264 3,503 2,983 4,266 965 1,010 885 931 656 591 570
Slide 13: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 10,000 2,500 1,400 8,000 2,000 1,200 28% 25% 24% 1,000 6,000 1,500 18% 18% 800 14% 14% 4,000 1,000 11% 600 2,000 500 400 5,469 8,024 8,151 8,982 1,557 2,028 1,971 1,576
Slide 14: Market Data
Market Data Share Price Data as on 30th June, 2019 25% 20% Bliss Sensex 15% 10% 5% 0% -5% -10% -15% -20% -25% -30% Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Shareholding Pattern as on th June, Price Data (30th June, 2019) INR Shareholding Pattern as 30 on 30
Slide 15: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d